Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Zonder, MD
Karmanos Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Duke Medical Center
Durham, North Carolina, United States
- Taussig Cancer Center- Cleveland Clinic
Cleveland, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2008
- Primary completion
- 31 May 2011
- Completion
- 31 Oct 2011
- Last update posted
- 25 Apr 2024
- Registered enrollment
- 23
- Registry id
- NCT00775502
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.